TABLE 1.
Patient demographics
| Number | 126 |
|---|---|
| Sex | |
| Male | 62 (48 %) |
| Female | 64 (52 %) |
| Age [years; median (range)] | 56 (30–91 %) |
| Histology | |
| SCC | 49 (39 %) |
| LCC | 23 (18 %) |
| Collision tumor (HGNEC with adenocarcinoma) | 18 (14 %) |
| Sites | |
| Anal | 5 (4 %) |
| Rectal | 53 (42 %) |
| Sigmoid | 9 (7 %) |
| Colon | 38 (30 %) |
| Cecum | 23 (18 %) |
| LVI | |
| Yes | 48 (84 %) |
| No | 9 (16 %) |
| PNI | |
| Yes | 18 (50 %) |
| No | 18 (50 %) |
| Median tumor size (range) | 4 (0.1–11) |
| AJCC stages | |
| 1 | 0 |
| 2 | 15 (12 %) |
| 3 | 26 (21 %) |
| 4 | 85 (67 %) |
| Resection of primary tumor | |
| Yes | 73 (58 %) |
| No | 53 (42 %) |
| Treatment of M0 diseases | |
| Surgery | 29 (71 %) |
| No surgery | 12 (29 %) |
| IBD | 8 (6 %) |
| Synchronous adenocarcinoma | 4 (4 %) |
| Metastatic disease | |
| Liver | 64 (51 %) |
| Lung | 11 (8 %) |
| Bone | 10 (7 %) |
| RPLN | 8 (6 %) |
| Peritoneal | 7 (5 %) |
| Inguinal lymph node | 5 (4 %) |
| Brain | 2 (2 %) |
Data are expressed as n (%) unless otherwise specified
SCC small cell carcinoma, LCC large cell carcinoma, HGNEC high-grade neuroendocrine carcinoma, LVI lymphovascular invasion, PNI perineural invasion, AJCC American Joint Committee on Cancer, IBD inflammatory bowel disease, RPLN retroperitoneal lymph nodes